Related Experiment Videos
Prostaglandin E1 in severe Raynaud's phenomenon.
Surgery
|December 1, 1982
Summary
Prostaglandin E1 (PGE1) significantly improved finger blood flow and healing in patients with severe Raynaud
Area of Science:
- Vascular Medicine
- Pharmacology
Background:
- Severe Raynaud's phenomenon can lead to finger sepsis and necrosis.
- Previous treatments like sympathectomy have limitations.
Purpose of the Study:
- To evaluate the efficacy of prostaglandin E1 (PGE1) in treating severe Raynaud's phenomenon with finger sepsis or necrosis.
Main Methods:
- Intravenous PGE1 administration for 72 hours in 21 patients.
- Comparison with saline placebo.
- Assessment of finger skin temperature, digital arterial flow, and pressure index.
- Surgical debridement of necrotic tissue when necessary.
Main Results:
- PGE1 significantly improved digital arterial flow, finger skin temperature, and pressure index compared to placebo.
- Symptomatic improvement observed in 12 of 13 patients with sepsis/necrosis (Group II).
- No deterioration and successful healing of debrided fingers post-PGE1 treatment.
Conclusions:
- PGE1 is an effective treatment for acute exacerbations of finger sepsis and necrosis in severe Raynaud's phenomenon.
- PGE1 offers a safe, repeatable alternative to sympathectomy with fewer side effects.
- Nail bed removal can prevent recurrent sepsis and necrosis.